Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.
Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01410344 (Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903)
Who cites it
19 citing papers in PubMed.
- Brief Report: Rebound HIV Viremia With Meningoencephalitis After Antiretroviral Therapy Interruption After Allogeneic Bone Marrow Transplant.Journal of acquired immune deficiency syndromes (1999) · 2022Trial
- Short Communication: Persistence of HIV After Allogeneic Bone Marrow Transplant in a Dually Infected Individual.AIDS research and human retroviruses · 2022Trial
- Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.The lancet. HIV · 2020Trial
- [Chinese expert consensus on the diagnosis and treatment of human immunodeficiency virus infection related diffuse large B cell lymphoma (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Lymphoproliferations in People Living with HIV: Oncogenic Pathways, Diagnostic Challenges, and New Therapeutic Opportunities.Cancers · 2025Review
- Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells.Nature medicine · 2024Article
- Management of Antiretroviral Therapy and Opportunistic Infections in People Living with HIV Undergoing Hematopoietic Stem Cell Transplant in British Columbia.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024Article
- Review
- Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee.Transplantation and cellular therapy · 2024Article
- Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials.Journal of the National Cancer Institute · 2022Article
- HIV-Associated Lymphomas: Progress and New Challenges.Journal of clinical medicine · 2022Review
- Promising Stem Cell therapy in the Management of HIV and AIDS: A Narrative Review.Biologics : targets & therapy · 2022Review
- Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Progress in the Treatment of HIV-Associated Lymphoma When Combined With the Antiretroviral Therapies.Frontiers in oncology · 2021Review
- Haemopoietic cell transplantation in patients living with HIV.The lancet. HIV · 2020Review
- From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation.Current HIV/AIDS reports · 2020Review
- [Clinical analysis in five patients with acute leukemia and HIV infection].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers.International journal of molecular sciences · 2020Review
- Treatment Disparities in Acute Leukemia Among HIV-positive Patients: Evidence from a Comprehensive National Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase II prospective multicenter trial. The primary endpoint was 100-day nonrelapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least a 7/8 HLA-matched unrelated donor. Indications for transplant were acute leukemia, myelodysplasia, and lymphoma. Conditioning was myeloablative or reduced intensity. There was no NRM at 100 days. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 41%. At 1 year, overall survival was 59%; deaths were from relapsed/progressive disease (n = 5), acute GVHD (n = 1), adult respiratory distress syndrome (n = 1), and liver failure (n = 1). In patients who achieved complete chimerism, cell-associated HIV DNA and inducible infectious virus in the blood were not detectable. Blood and Marrow Transplant Clinical Trials Network 0903/AIDS Malignancy Consortium 080 was registered at www.clinicaltrials.gov (no. NCT01410344).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.